UGT1A1 Irinotecan toxicity
UGT1A1 Irinotecan toxicity-994
Irinotecan
Irinotecan (Camptosar®) is used, or under evaluation, in a broad spectrum of solid tumors, and is often prescribed for treating patients with metastatic cancer of the colon or rectum, especially when 5-fluorouracil treatment has not been entirely successful. Severe toxicity (eg, grade 4 neutropenia) is commonly observed in cancer patients receiving irinotecan who carry the UGT1A1*28 allele, also called TA. This test result will provide valuable information to physicians prior to initiating or modifying treatment or supplementing treatment with additional drugs. UGT1A1 variants have also been reported in patients with disorders of bilirubin metabolism, such as Crigler-Najjar Types I and II, as well as Gilbert syndrome. Between 80% to 100% of Caucasian patients with Gilbert syndrome are reported to have either one or two copies of UGT1A1*28. G71R (*6), a UGT1A1 variant reported in Asian patients with Gilbert syndrome, is not detected by this assay.
Immediately after collection, mix sample thoroughly by gentle inversion, 8 - 10 times, to prevent clotting
Lavender (EDTA), 10mL
Yellow ACD (A or B)
Yellow ACD (A or B)
Molecular Medicare Billing Request
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.
Ambient (preferred) - 7 days
Refrigerated - 1 month
Frozen - 2 years
- Hemolysis
- Quantity not sufficient for analysis
- Improper container/anticoagulant
Polymerase chain reaction (PCR) and capillary electrophoresis
An interpretive report will be provided
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.